Foundations
A guided introduction to a disease that can look different from person to person—and change over time.
60-second explanation
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. The immune system becomes persistently active against parts of the body, and inflammation can affect the skin, joints, kidneys, blood, nervous system, lungs, heart, or blood vessels.
Symptoms and severity vary widely. Many people experience periods of greater disease activity, often called flares, and quieter periods. No single symptom or laboratory test confirms SLE on its own; diagnosis depends on the overall clinical pattern and the exclusion of reasonable alternatives.
“Autoantibodies are present” and “active organ inflammation is occurring” are not interchangeable. Clinicians combine symptoms, examination, laboratory trends, and sometimes tissue biopsy.
In many models, genetic susceptibility and environmental exposures interact with imperfect clearance of cellular material. Nucleic-acid sensing, interferon signaling, altered B- and T-cell states, autoantibodies, immune complexes, complement, and tissue-specific responses can then reinforce one another.
This is a network, not a universal six-step chain. Different biological routes may dominate in different people or at different points in the same person’s disease.
Clinicians may use medical history, physical examination, blood counts, kidney function, urine testing, complement levels, and antibodies such as ANA, anti-double-stranded DNA, and anti-Smith. Classification criteria help research studies assemble comparable groups; they are not a do-it-yourself diagnostic checklist.
Care aims to control disease activity, prevent irreversible organ damage, minimize treatment toxicity, support quality of life, and reduce cardiovascular, infection, bone, and reproductive-health risks. The safest choice depends heavily on the organs involved, disease activity, other health conditions, prior response, and patient priorities.
This overview is anchored to NIAMS patient information (opens in a new tab), the 2025 ACR guideline (opens in a new tab), and EULAR recommendations (opens in a new tab). Mechanistic claims are progressively moving into the audited claim ledger.
Key concepts
These summaries deliberately state the boundary of each claim.
Autoreactive immune cells and antibodies can persist when checkpoints that normally prevent responses against self are bypassed or overwhelmed.
Multiple mechanisms can produce loss of tolerance; no single checkpoint explains all SLE. The evidence includes genetic associations, rare causal variants, cell profiling, and functional experiments. Inspect the claim ledger.
Interferon-related gene activity is elevated in a substantial subgroup and is linked to disease biology and a validated treatment target.
The interferon signature is heterogeneous and is not a stand-alone diagnostic test or guaranteed predictor of response. Inspect the audited interferon hub.
Autoreactive B cells, plasmablasts, and plasma cells contribute to autoantibody production and other immune functions in SLE.
B cells also present antigen and produce cytokines. Different therapies affect distinct B-cell compartments. Inspect BAFF-targeted evidence or the CAR-T hub.
Ultraviolet light, infections, medicines, hormones, and other exposures are studied as modifiers of risk or activity, but causality and individual prediction vary.
A population-level association cannot determine what caused one person’s lupus or flare. Inspect an example with support and causal boundaries.